Answers are grounded in this paper and cite their sources.
Mechanistic assignment in cancer immunology often assumes that durable antitumor effects reflect sustained pharmacologic pressure on tumor cells. Dihydroartemisinin (DHA) provides a useful test case for revisiting this assumption because clinically achievable systemic exposure is brief and free-drug availability is constrained by substantial protein binding. We therefore propose that brief systemic DHA exposure may act as a pharmacokinetically constrained immune-conditioning pulse whose durable antitumor effects, when present, could involve persistent tumor-intrinsic injury, immune relay, or both. Within this framework, transient tumor or stromal stress may be converted into longer-lived antitumor activity through myeloid-state transition, dendritic-cell activation, relief of immune exclusion, and subsequent CD8 + T-cell priming. Current evidence does not yet establish a dominant immune mechanism under exposure-matched conditions. Suppressive myeloid-state change, a tumor stress–dendritic cell–CD8 + T-cell axis, and direct lymphocyte responsiveness are competing hypotheses for exposure-matched testing alongside direct tumor-cell effects. This framework informs exposure-matched experimental design, biomarker development, and rational immunotherapy combinations, and provides a falsifiable prioritization scheme based on exposure matching, temporal precedence, persistence after washout, and in vivo necessity.
No takes yet. Share an insight, caveat, or question.
Wei et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: